*The significant market potential in recurrent pericarditis (estimated to exceed $1 billion by 2028) and heart failure, coupled with CardiolRx's Orphan Drug Designation, positions the company for potential long-term growth, contingent on successful clinical trial outcomes.
*Investors should monitor the progression of the pivotal Phase III MAVERIC trial for recurrent pericarditis and the continued development of CRD-38, while acknowledging the inherent risks associated with clinical development, capital requirements, and competition from larger pharmaceutical players.